ClinicalTrials.gg
RecruitingNCT05909761Updated Oct 29, 2026

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

An observational study in Neuromyelitis Optica Spectrum Disorder and Pregnancy Related, sponsored by Amgen. Recruiting at 1 site in United States. Open to female participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Amgen · Observational

How we know

Updated Oct 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
60
Ages
15 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Neuromyelitis Optica with a site in United States — 16 open to participants now, 21 under way, 2 of them phase 3. Neuromyelitis Optica · United States.

Planned enrollment
11th of 15
60 · median 112
Started
2027
the only one that year
Observational
15 of 52
8 open now
Primary completion
2032-10
later than 17 of 20 live
Registered
42nd of 52
by date
Lead sponsor
3 of 52
Amgen

Among the 52 studies in Neuromyelitis Optica with a site in United States, this one is the 11th largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2027, is one of 15 observational ones, reaches primary completion later than 17 of the 20 other live ones, and was the 42nd registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

16 of the 52 studies in Neuromyelitis Optica with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 15 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Neuromyelitis Optica with a site in United States, or all of them as a file.
02

Study summary

This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or within 6 months preceding conception. Pregnancy-related data, potential confounding factors and information related to pregnancy outcome will be collected. The schedule of office visits and all treatment regimens will be determined by the treating healthcare provider. Duration of the study is 10 years, at minimum.

Read the detailed description

Acquired from Horizon in 2024.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder
  • Pregnancy Related

Browse trials for

Keywords

  • Neuromyelitis Optica Spectrum Disorder
  • Pregnancy
  • UPLIZNA
  • inebilizumab
  • birth complications
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of participants who have been exposed to UPLIZNA during pregnancy and have signed an informed consent form (ICF).

Eligibility criteria

Inclusion Criteria:

  • Provide
  • Are a female of with a confirmed or suspected diagnosis of NMOSD
  • Have been exposed to UPLIZNA during pregnancy as defined by receipt of any dose during pregnancy or within 6 months preceding conception

Note: Other Protocol Defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
60 participants (estimated)
Patient registry
No

Interventions

  • DrugInebilizumabStudies of InebilizumabInebilizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.

    Also known as: inebilizumab-cdon

06

What researchers measure

Primary outcomes

  1. Number of newborns with Major Congenital Malformations (MCMs)

    Time frame: Minimum of 10 years

  2. Number of newborns with Preterm birth

    Time frame: Minimum of 10 years

  3. Number of newborns with low birth weight

    Time frame: Minimum of 10 years

  4. Number of stillbirths

    Time frame: Minimum of 10 years

Secondary outcomes

  1. Number of newborns with Minor Congenital Malformations

    Time frame: Minimum of 10 years

  2. Number of infants with developmental milestone abnormalities

    Time frame: Minimum of 10 years

  3. Number of infants with neurologic abnormalities

    Time frame: Minimum of 10 years

  4. Number of infants with immune system development abnormalities

    Time frame: Minimum of 10 years

  5. Number of Spontaneous Abortions

    Time frame: Minimum of 10 years

  6. Number of Induced or Elective Abortions

    Time frame: Minimum of 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Oct 2032, 69 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jun 18, 2023
StartEst.
Jan 15, 2027was Oct 2026
Primary completionEst.
Oct 31, 2032
CompletionEst.
Oct 31, 2032
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Jan 15, 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Oct 15, 2026→Jan 15, 2027
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05909761
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jan 15, 2027 (estimated)
Primary completion
Oct 31, 2032 (estimated)
Completion
Oct 31, 2032 (estimated)
Last update
Oct 29, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion